428:
951:
The results showed that after injection the concentration of plasma MA increased rapidly. The meantime of peak plasma MA level was 3rd day, there was a linear relationship between log of plasma MA concentration and time (day) after administration in all subjects, elimination phase half-life t1/2β =
1065:
446:
34:
27:
607:
17α-Hydroxyprogesterone caproate is a depot progestogen which is entirely free of side actions. The dose required to induce secretory changes in primed endometrium is about 250 mg. per menstrual cycle.
683:
Henzl MR, Edwards JA (10 November 1999). "Pharmacology of
Progestins: 17α-Hydroxyprogesterone Derivatives and Progestins of the First and Second Generation". In Sitruk-Ware R, Mishell DR (eds.).
451:
1086:
844:
Becker H, Düsterberg B, Klosterhalfen H (1980). "" [Bioavailability of
Cyproterone Acetate after Oral and Intramuscular Application in Men].
879:
Moltz L, Haase F, Schwartz U, Hammerstein J (May 1983). "" [Efficacy of Intra muscularly
Applied Cyproterone Acetate in Hyperandrogenism].
441:
1029:
1002:
975:
925:
828:
721:
694:
630:
573:
536:
509:
482:
659:
600:
943:"Pharmacokinetics of megestrol acetate in women receiving IM injection of estradiol-megestrol long-acting injectable contraceptive"
1081:
146:
168:
124:
652:
Pharmacology of the
Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Agents
337:
234:
212:
316:
320:
80:
102:
737:
Sang GW (April 1994). "Pharmacodynamic effects of once-a-month combined injectable contraceptives".
942:
1025:
1019:
998:
992:
971:
965:
921:
915:
896:
861:
824:
789:
754:
717:
690:
665:
655:
626:
620:
596:
569:
553:
532:
526:
505:
499:
478:
472:
190:
808:
888:
853:
816:
781:
746:
561:
772:
Toppozada MK (April 1994). "Existing once-a-month combined injectable contraceptives".
1075:
785:
750:
333:
711:
684:
647:
590:
565:
820:
447:
Template:Potencies and durations of natural estrogens by intramuscular injection
669:
592:
The
Principles and Practice of Hormone Therapy in Gynaecology and Obstetrics
892:
422:
900:
865:
793:
758:
501:
Geburtshilfe und Gynäkologie: Physiologie und
Pathologie der Reproduktion
857:
68:
498:
Knörr K, Knörr-Gärtner H, Beller FK, Lauritzen C (8 March 2013).
73:
1018:
King TL, Brucker MC, Kriebs JM, Fahey JO (21 October 2013).
452:
Template:Parenteral durations of androgens/anabolic steroids
560:. Springer Science & Business Media. pp. 309–332.
815:. Springer Science & Business Media. pp. 67–111.
991:
Artini PG, Genazzani AR, Petraglia F (11 December 2001).
558:
Ovarian
Function and its Disorders: Diagnosis and Therapy
970:. Springer Science & Business Media. pp. 429–.
920:. Springer Science & Business Media. pp. 114–.
554:"Hormonal Treatment of Disorders of the Menstrual Cycle"
531:. Springer Science & Business Media. pp. 554–.
1058:
1050:
1046:
63:
809:"Pharmacokinetics of Contraceptive Steroids in Humans"
403:
648:"Effects, Duration of Action and Metabolism in Man"
42:Parenteral potencies and durations of progestogens
1043:Editors can experiment in this template's sandbox
1024:. Jones & Bartlett Publishers. pp. 495–.
964:Runnebaum BC, Rabe T, Kiesel L (6 December 2012).
686:Progestins and Antiprogestins in Clinical Practice
622:Praktische Gynäkologie: für Studierende und Ärzte
471:Knörr K, Beller FK, Lauritzen C (17 April 2013).
338:
654:. Vol. II. Pergamon Press. pp. 13–24.
813:Contraceptive Steroids: Pharmacology and Safety
402:In divided doses (2 × 125 or 250 mg for
28:
8:
947:The Chinese Journal of Clinical Pharmacology
528:Clinical Endocrinology: Theory and Practice
689:. Taylor & Francis. pp. 101–132.
56:
35:
21:
15:
914:Wright JC, Burgess DJ (29 January 2012).
390:Never marketed or approved by this route.
1087:Templates that generate named references
625:. Walter de Gruyter. pp. 598, 601.
372:Usually dosed every two to three months.
994:Advances in Gynecological Endocrinology
967:Female Contraception: Update and Trends
463:
442:Template:Oral potencies of progestogens
297:
288:
398:
396:
16:
336:is ~25 (15–50) mg/day. The
55:
52:
49:
46:
7:
941:Chu YH, Li Q, Zhao ZF (April 1986).
407:
345:of OHPC is 250 to 500 mg/month.
917:Long Acting Injections and Implants
332:Progesterone production during the
811:. In Gregoire AT, Blye RP (eds.).
504:. Springer-Verlag. pp. 583–.
477:. Springer-Verlag. pp. 214–.
14:
343:Tooltip ovulation-inhibiting dose
881:Geburtshilfe und Frauenheilkunde
426:
716:. Academic Press. p. 114.
556:. In Horsky J, Presl K (eds.).
1:
525:Labhart A (6 December 2012).
997:. CRC Press. pp. 105–.
786:10.1016/0010-7824(94)90029-9
751:10.1016/0010-7824(94)90033-7
566:10.1007/978-94-009-8195-9_11
53:Dose for specific uses (mg)
821:10.1007/978-1-4613-2241-2_4
381:Usually dosed once monthly.
354:Duration of action in days.
1103:
1042:
646:Ferin J (September 1972).
595:. de Gruyter. p. 49.
552:Horský J, Presl J (1981).
363:Usually given for 14 days.
1066:Subpages of this template
289:
233:
72:
67:
62:
846:Urologia Internationalis
713:Sex Hormone Pharmacology
474:Lehrbuch der Gynäkologie
213:Norethisterone enanthate
147:Hydroxyprogest. caproate
125:Hydroxyprogest. acetate
893:10.1055/s-2008-1036893
807:Goebelsmann U (1986).
619:Pschyrembel W (1968).
431:Template documentation
406:, 10 × 20 mg for
321:subcutaneous injection
81:Algestone acetophenide
710:Brotherton J (1976).
1082:Medication templates
650:. In Tausk M (ed.).
169:Medroxyprog. acetate
103:Gestonorone caproate
43:
1021:Varney's Midwifery
292:Notes and sources:
1031:978-1-284-02542-2
1004:978-1-84214-071-0
977:978-3-642-73790-9
952:14.35 ± 9.1 days.
927:978-1-4614-0554-2
858:10.1159/000280353
830:978-1-4613-2241-2
723:978-0-12-137250-7
696:978-0-8247-8291-7
632:978-3-11-150424-7
575:978-94-009-8195-9
538:978-3-642-96158-8
511:978-3-642-95583-9
484:978-3-662-00942-0
421:
420:
191:Megestrol acetate
1094:
1062:
1054:
1036:
1035:
1015:
1009:
1008:
988:
982:
981:
961:
955:
954:
938:
932:
931:
911:
905:
904:
876:
870:
869:
841:
835:
834:
804:
798:
797:
769:
763:
762:
734:
728:
727:
707:
701:
700:
680:
674:
673:
643:
637:
636:
616:
610:
609:
586:
580:
579:
549:
543:
542:
522:
516:
515:
495:
489:
488:
468:
432:
430:
429:
411:
409:
405:
400:
391:
388:
382:
379:
373:
370:
364:
361:
355:
352:
346:
344:
340:
330:
324:
313:
307:
302:
75:
70:
65:
58:
44:
37:
30:
23:
1102:
1101:
1097:
1096:
1095:
1093:
1092:
1091:
1072:
1071:
1070:
1069:
1064:
1056:
1044:
1041:
1040:
1039:
1032:
1017:
1016:
1012:
1005:
990:
989:
985:
978:
963:
962:
958:
940:
939:
935:
928:
913:
912:
908:
878:
877:
873:
843:
842:
838:
831:
806:
805:
801:
771:
770:
766:
736:
735:
731:
724:
709:
708:
704:
697:
682:
681:
677:
662:
645:
644:
640:
633:
618:
617:
613:
603:
589:Ufer J (1969).
588:
587:
583:
576:
551:
550:
546:
539:
524:
523:
519:
512:
497:
496:
492:
485:
470:
469:
465:
460:
438:
433:
427:
425:
417:
416:
415:
414:
401:
394:
389:
385:
380:
376:
371:
367:
362:
358:
353:
349:
342:
331:
327:
314:
310:
303:
299:
293:
41:
12:
11:
5:
1100:
1098:
1090:
1089:
1084:
1074:
1073:
1055:and testcases
1038:
1037:
1030:
1010:
1003:
983:
976:
956:
933:
926:
906:
887:(5): 281–287.
871:
852:(6): 381–385.
836:
829:
799:
780:(4): 293–301.
764:
745:(4): 361–385.
729:
722:
702:
695:
675:
661:978-0080168128
660:
638:
631:
611:
601:
581:
574:
544:
537:
517:
510:
490:
483:
462:
461:
459:
456:
455:
454:
449:
444:
437:
434:
424:
423:
419:
418:
413:
412:
392:
383:
374:
365:
356:
347:
325:
308:
296:
295:
294:
291:
290:
287:
286:
283:
280:
277:
274:
270:
269:
266:
263:
260:
257:
253:
252:
249:
246:
243:
240:
237:
231:
230:
227:
224:
221:
218:
215:
209:
208:
205:
202:
199:
196:
193:
187:
186:
183:
180:
177:
174:
171:
165:
164:
161:
158:
155:
152:
149:
143:
142:
139:
136:
133:
130:
127:
121:
120:
117:
114:
111:
108:
105:
99:
98:
95:
92:
89:
86:
83:
77:
76:
71:
66:
60:
59:
54:
51:
48:
40:
39:
32:
25:
17:
13:
10:
9:
6:
4:
3:
2:
1099:
1088:
1085:
1083:
1080:
1079:
1077:
1067:
1060:
1052:
1048:
1033:
1027:
1023:
1022:
1014:
1011:
1006:
1000:
996:
995:
987:
984:
979:
973:
969:
968:
960:
957:
953:
948:
944:
937:
934:
929:
923:
919:
918:
910:
907:
902:
898:
894:
890:
886:
882:
875:
872:
867:
863:
859:
855:
851:
847:
840:
837:
832:
826:
822:
818:
814:
810:
803:
800:
795:
791:
787:
783:
779:
775:
774:Contraception
768:
765:
760:
756:
752:
748:
744:
740:
739:Contraception
733:
730:
725:
719:
715:
714:
706:
703:
698:
692:
688:
687:
679:
676:
671:
667:
663:
657:
653:
649:
642:
639:
634:
628:
624:
623:
615:
612:
608:
604:
602:9783110006148
598:
594:
593:
585:
582:
577:
571:
567:
563:
559:
555:
548:
545:
540:
534:
530:
529:
521:
518:
513:
507:
503:
502:
494:
491:
486:
480:
476:
475:
467:
464:
457:
453:
450:
448:
445:
443:
440:
439:
435:
399:
397:
393:
387:
384:
378:
375:
369:
366:
360:
357:
351:
348:
341:
335:
329:
326:
322:
318:
317:intramuscular
315:All given by
312:
309:
306:
301:
298:
284:
281:
278:
275:
272:
271:
267:
264:
261:
258:
255:
254:
250:
247:
244:
241:
238:
236:
232:
228:
225:
222:
219:
216:
214:
211:
210:
206:
203:
200:
197:
194:
192:
189:
188:
184:
181:
178:
175:
172:
170:
167:
166:
162:
159:
156:
153:
150:
148:
145:
144:
140:
137:
134:
131:
128:
126:
123:
122:
118:
115:
112:
109:
106:
104:
101:
100:
96:
93:
90:
87:
84:
82:
79:
78:
61:
45:
38:
33:
31:
26:
24:
19:
18:
1020:
1013:
993:
986:
966:
959:
950:
946:
936:
916:
909:
884:
880:
874:
849:
845:
839:
812:
802:
777:
773:
767:
742:
738:
732:
712:
705:
685:
678:
651:
641:
621:
614:
606:
591:
584:
557:
547:
527:
520:
500:
493:
473:
466:
386:
377:
368:
359:
350:
334:luteal phase
328:
311:
304:
300:
235:Progesterone
20:
1076:Categories
458:References
670:278011135
273:Aq. susp.
256:Aq. soln.
239:Oil soln.
217:Oil soln.
207:>14 d
195:Aq. susp.
185:14–50+ d
173:Aq. susp.
151:Oil soln.
129:Aq. susp.
107:Oil soln.
85:Oil soln.
47:Compound
436:See also
305:Sources:
229:11–52 d
97:14–32 d
1049:|
901:6223851
866:6452729
794:8013216
759:8013220
285:7–14 d
220:100–200
163:5–21 d
160:250–500
154:250–500
141:9–16 d
119:8–13 d
1063:pages.
1059:create
1051:mirror
1047:create
1028:
1001:
974:
924:
899:
864:
827:
792:
757:
720:
693:
668:
658:
629:
599:
572:
535:
508:
481:
276:50–200
268:1–2 d
251:2–6 d
176:50–100
94:75–150
110:25–50
69:POICD
50:Form
1026:ISBN
999:ISBN
972:ISBN
922:ISBN
897:PMID
862:PMID
825:ISBN
790:PMID
755:PMID
718:ISBN
691:ISBN
666:OCLC
656:ISBN
627:ISBN
597:ISBN
570:ISBN
533:ISBN
506:ISBN
479:ISBN
404:OHPC
74:CICD
889:doi
854:doi
817:doi
782:doi
747:doi
562:doi
339:OID
319:or
242:200
223:200
179:150
132:350
64:TFD
57:DOA
1078::
949:.
945:.
895:.
885:43
883:.
860:.
850:35
848:.
823:.
788:.
778:49
776:.
753:.
743:49
741:.
664:.
605:.
568:.
410:).
408:P4
395:^
226:50
204:25
182:25
1068:.
1061:)
1057:(
1053:)
1045:(
1034:.
1007:.
980:.
930:.
903:.
891::
868:.
856::
833:.
819::
796:.
784::
761:.
749::
726:.
699:.
672:.
635:.
578:.
564::
541:.
514:.
487:.
323:.
282:–
279:–
265:–
262:–
259:?
248:–
245:–
201:–
198:-
157:–
138:–
135:–
116:–
113:–
91:–
88:-
36:e
29:t
22:v
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.